• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical, Microbiological, and Antibiotic Treatment Characteristics of Bacterial Infections in Patients with Liver Cirrhosis in China: A Multicenter Study.中国肝硬化患者细菌感染的临床、微生物学及抗生素治疗特征:一项多中心研究
J Clin Transl Hepatol. 2025 Aug 28;13(8):644-654. doi: 10.14218/JCTH.2025.00211. Epub 2025 Jul 3.
2
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.全球肝硬化住院患者感染的流行情况和特征及临床结局:CLEARED 联盟的一项前瞻性队列研究。
Lancet Gastroenterol Hepatol. 2024 Nov;9(11):997-1009. doi: 10.1016/S2468-1253(24)00224-3. Epub 2024 Sep 5.
3
Multidrug-resistant coinfection with multiple microbes: a retrospective study on its risk factors and clinical outcomes.多重微生物的多重耐药合并感染:关于其危险因素和临床结局的回顾性研究。
mSystems. 2025 Jul 10:e0175724. doi: 10.1128/msystems.01757-24.
4
Bacterial resistance profile and its association with poor outcome among cirrhosis patients attending a tertiary care referral center in northern India.印度北部一家三级医疗转诊中心肝硬化患者的细菌耐药情况及其与不良预后的关联。
Indian J Gastroenterol. 2025 Apr;44(2):198-207. doi: 10.1007/s12664-024-01712-0. Epub 2025 Feb 8.
5
Six-year retrospective analysis of the epidemiology and risk factors of multidrug-resistant bloodstream infections in oncology patients in Jiangxi, China.中国江西肿瘤患者多重耐药血流感染的流行病学及危险因素的六年回顾性分析
Microbiol Spectr. 2025 Aug 14:e0146825. doi: 10.1128/spectrum.01468-25.
6
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis.抗生素预防肝硬化患者自发性细菌性腹膜炎:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD013125. doi: 10.1002/14651858.CD013125.pub2.
7
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
8
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
9
Genomic surveillance for multidrug-resistant or hypervirulent Klebsiella pneumoniae among United States bloodstream isolates.美国血流感染分离株中多重耐药或高毒力肺炎克雷伯菌的基因组监测。
BMC Infect Dis. 2022 Jul 7;22(1):603. doi: 10.1186/s12879-022-07558-1.
10
A single-center retrospective study of pathogen distribution and antibiotic resistance of bloodstream infections in emergency department.急诊科血流感染病原体分布及抗生素耐药性的单中心回顾性研究
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Nov 28;49(11):1799-1807. doi: 10.11817/j.issn.1672-7347.2024.240333.

本文引用的文献

1
Evidence-based incorporation of key parameters into MELD score for acute-on-chronic liver failure.基于证据将关键参数纳入慢性重型肝炎的终末期肝病模型评分。
eGastroenterology. 2024 Oct 1;2(3):e100101. doi: 10.1136/egastro-2024-100101. eCollection 2024 Sep.
2
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.全球肝硬化住院患者感染的流行情况和特征及临床结局:CLEARED 联盟的一项前瞻性队列研究。
Lancet Gastroenterol Hepatol. 2024 Nov;9(11):997-1009. doi: 10.1016/S2468-1253(24)00224-3. Epub 2024 Sep 5.
3
Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat.高毒力且耐碳青霉烯类的肺炎克雷伯菌:全球公共卫生威胁。
Microbiol Res. 2024 Nov;288:127839. doi: 10.1016/j.micres.2024.127839. Epub 2024 Aug 11.
4
Bacterial Infections in Acute-on-chronic Liver Failure: Epidemiology, Diagnosis, Pathogenesis, and Management.慢性肝衰竭急性发作时的细菌感染:流行病学、诊断、发病机制及管理
J Clin Transl Hepatol. 2024 Jul 28;12(7):667-676. doi: 10.14218/JCTH.2024.00137. Epub 2024 Jun 20.
5
Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis.质子泵抑制剂增加肝硬化患者死亡、失代偿和感染的长期风险:一项荟萃分析。
Dig Dis Sci. 2024 Jan;69(1):289-297. doi: 10.1007/s10620-023-08150-6. Epub 2023 Nov 15.
6
"Superbugs" with hypervirulence and carbapenem resistance in Klebsiella pneumoniae: the rise of such emerging nosocomial pathogens in China.肺炎克雷伯菌中具有高毒力和碳青霉烯耐药性的“超级细菌”:此类新出现的医院病原体在中国的兴起。
Sci Bull (Beijing). 2023 Nov 15;68(21):2658-2670. doi: 10.1016/j.scib.2023.09.040. Epub 2023 Sep 29.
7
Infection risk and management strategies for patients with cirrhosis taking proton pump inhibitors.肝硬化患者使用质子泵抑制剂的感染风险及管理策略。
Am J Health Syst Pharm. 2023 Jul 21;80(15):967-973. doi: 10.1093/ajhp/zxad089.
8
Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay.肝硬化患者细菌感染的临床和微生物学特征。来自阿根廷和乌拉圭的前瞻性队列研究。
Ann Hepatol. 2023 Jul-Aug;28(4):101097. doi: 10.1016/j.aohep.2023.101097. Epub 2023 Apr 6.
9
Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review.肝硬化患者多重耐药菌感染的患病率及治疗管理:一项叙述性综述
Antibiotics (Basel). 2022 Feb 11;11(2):232. doi: 10.3390/antibiotics11020232.
10
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.利福昔明-α可减少肝硬化和肝性脑病中的肠道来源的炎症和粘蛋白降解:RIFSYS 随机对照试验。
J Hepatol. 2022 Feb;76(2):332-342. doi: 10.1016/j.jhep.2021.09.010. Epub 2021 Sep 24.

中国肝硬化患者细菌感染的临床、微生物学及抗生素治疗特征:一项多中心研究

Clinical, Microbiological, and Antibiotic Treatment Characteristics of Bacterial Infections in Patients with Liver Cirrhosis in China: A Multicenter Study.

作者信息

Zhang Xiuding, Weng Haoda, Deng Qinzhi, Deng Min, Wu Xuwei, Huang Zuxiong, Liu Shourong, Wu Rui, Ma Chunlian, Xu Yao, Zhong Jianfeng, Yang Jie, Wu Yinxia, Shen Huajiang, Ding Feng, Wang Fang, Zhai Xuezhen, Peng Chunxian, Ren Haotang, Jin Jie, Xu Xiangfei, Li Xiaofei, Ye Xiaoting, Qian Guoqing, Sun Shuilin, Yao Xuebing, Miao Haifeng, Xiao Qianggu, Ye Shaoheng, Zhang Qing, Xu Xinyi, Yu Xia, Yu Yue, Lan Yan, Tu Huilan, Xu Xianbin, Zhang Xinrong, Huang Rui, Qian Xiaohan, Yang Qiao, Sheng Jifang, Shi Yu

机构信息

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Department of Infectious Diseases, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.

出版信息

J Clin Transl Hepatol. 2025 Aug 28;13(8):644-654. doi: 10.14218/JCTH.2025.00211. Epub 2025 Jul 3.

DOI:10.14218/JCTH.2025.00211
PMID:40862284
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12375819/
Abstract

BACKGROUND AND AIMS

Epidemiological data on bacterial infections in cirrhosis in China remain limited. Therefore, we aimed to conduct a multicenter study to investigate the characteristics and outcomes of patients with cirrhosis and bacterial infections in China.

METHODS

We retrospectively enrolled 1,438 hospitalized adult patients with cirrhosis and bacterial or fungal infections from 24 hospitals across China between January 2018 and September 2024. Data on demographics, clinical features, microbiology, treatment, and outcomes were collected.

RESULTS

A total of 1,783 infection episodes were recorded, including 1,668 first infections and 115 second infections. Most infections were community-acquired (86.6%). Pneumonia was the most common infection type (26.7%), followed by spontaneous bacterial peritonitis (19.5%) and spontaneous bacteremia (14.1%). Among 754 pathogens isolated from 620 patients, Klebsiella pneumoniae (20.1%) was nearly as common as (21.7%). Multidrug-resistant (MDR) organisms accounted for 41.0% of all isolates, with extended-spectrum β-lactamase-producing being the most prevalent MDR strain (8.9% of patients). Adherence to empirical antibiotic treatment guidelines from the European Association for the Study of the Liver was significantly lower in this cohort compared to the global study (21.5% vs. 61.2%, < 0.001), accompanied by a lower clinical resolution rate (63.5% vs. 79.8%, < 0.001).

CONCLUSIONS

The clinical and microbiological characteristics of bacterial infections in patients with cirrhosis in China differ substantially from those reported in other regions. These findings highlight the need for region-specific management and prevention strategies, particularly in light of the changing microbiological landscape, high MDR prevalence, and suboptimal antibiotic practices.

摘要

背景与目的

中国肝硬化患者细菌感染的流行病学数据仍然有限。因此,我们旨在开展一项多中心研究,以调查中国肝硬化合并细菌感染患者的特征及预后。

方法

我们回顾性纳入了2018年1月至2024年9月期间来自中国24家医院的1438例住院成年肝硬化合并细菌或真菌感染患者。收集了人口统计学、临床特征、微生物学、治疗及预后等数据。

结果

共记录到1783次感染发作,其中包括1668次首次感染和115次二次感染。大多数感染为社区获得性(86.6%)。肺炎是最常见的感染类型(26.7%),其次是自发性细菌性腹膜炎(19.5%)和自发性菌血症(14.1%)。在从620例患者中分离出的754种病原体中,肺炎克雷伯菌(20.1%)与[此处原文缺失一种菌名](21.7%)几乎同样常见。多重耐药(MDR)菌占所有分离株的41.0%,产超广谱β-内酰胺酶的[此处原文缺失一种菌名]是最常见的MDR菌株(占患者的8.9%)。与全球研究相比,该队列中遵循欧洲肝脏研究协会经验性抗生素治疗指南的比例显著更低(21.5%对61.2%,P<0.001),临床缓解率也更低(63.5%对79.8%,P<0.001)。

结论

中国肝硬化患者细菌感染的临床和微生物学特征与其他地区报道的有很大差异。这些发现凸显了制定针对特定地区的管理和预防策略的必要性,尤其是鉴于微生物格局的变化、高MDR患病率以及不理想的抗生素使用情况。